Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

315

Participants

Timeline

Start Date

September 21, 2021

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2026

Conditions
Prostate Cancer
Interventions
DRUG

Apalutamide 60mg Tab

4 tablets by mouth once a day for 24 weeks

DRUG

Abiraterone Acetate 250mg

4 tablets by mouth on an empty stomach once a day for 16 weeks

DRUG

Prednisone 5mg Tab

1 tablet by mouth once daily while taking abiraterone acetate

DRUG

Docetaxel

Infusion every 3 weeks for 6 cycles (each cycle has 3 weeks)

DRUG

Niraparib 100mg Oral Capsule

3 capsules by mouth once daily for 16 weeks

DRUG

Atezolizumab

1200mg infusion every 3 weeks for 6 cycles

Trial Locations (9)

77030

RECRUITING

U.T. MD Anderson Cancer Center, Houston

95817

RECRUITING

University of California Davis, Sacramento

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle

02115

RECRUITING

Brigham & Women's Hospital, Boston

48109-5946

RECRUITING

University of Michigan Health, Ann Arbor

V5Z 1M9

RECRUITING

Vancouver Prostate Centre, Vancouver

N6A 5W9

RECRUITING

London Health Sciences Centre, London

K1H 8L6

RECRUITING

Ottawa Hospital Research Institute (OHRI), Ottawa

M5G 2C4

RECRUITING

University Health Network, Toronto

All Listed Sponsors
collaborator

Janssen Inc.

INDUSTRY

collaborator

University Health Network, Toronto

OTHER

lead

University of British Columbia

OTHER